A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates

被引:8
|
作者
Bartlett, Emmalene J. [1 ]
Cruz, Ann-Marie [1 ]
Boonyaratanakornkit, Jim [1 ]
Esker, Janice [1 ]
Castano, Adam [1 ]
Skiadopoulos, Mario H. [1 ]
Collins, Peter L. [1 ]
Murphy, Brian R. [1 ]
Schmidt, Alexander C. [1 ]
机构
[1] NIAID, Infect Dis Lab, RNA Viruses Sect, NIH,US Dept HHS, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Human parainfluenza virus; C protein; Vaccine candidates; RESPIRATORY SYNCYTIAL VIRUS; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; AFRICAN-GREEN MONKEYS; L-POLYMERASE PROTEIN; SENDAI-VIRUS; RNA-SYNTHESIS; REVERSE GENETICS; YOUNG-CHILDREN; GENOME REPLICATION;
D O I
10.1016/j.vaccine.2009.10.069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A novel recombinant human parainfluenza virus type 1 (rHPIV1), rHPIV1-C+P, in which the overlapping open reading frames of the C and P genes were separated in order to introduce mutations into the C gene without affecting P, was generated Infectious rHPIV1-C+P was readily recovered and replicated as efficiently as HPIV1 wild type (wt) in vitro and in African green monkeys (AGMs) rHPIV1-C+P expressed increased levels of C protein and, surprisingly. activated the type I IFN and apoptosis responses more strongly than HPIV1 wt. rHPIV1-C+P provided a useful backbone for recovering an attenuated P/C gene mutation (Delta 84-85), which was previously unrecoverable, likely due to detrimental effects of the deletion on the P protein rHPIV1-C Delta 84-85 +P and an additional mutant, rHPIV1-C Delta 169-170+P. were found to replicate to similar titers in vitro and to activate the type I IFN and apoptosis responses to a similar degree as rHPIV1-C+P rHPIV1-C Delta 84-85+P was found to be highly attenuated in AGMs, and all viruses were immunogenic and effective in protecting AGMs against challenge with HPIV1 wt. rHPIV1-C Delta 84-85+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1 Published by Elsevier Ltd.
引用
收藏
页码:767 / 779
页数:13
相关论文
共 8 条
  • [1] Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine
    Mackow, Natalie
    Amaro-Carambot, Emerito
    Liang, Bo
    Surman, Sonja
    Lingemann, Matthias
    Yang, Lijuan
    Collins, Peter L.
    Munir, Shirin
    JOURNAL OF VIROLOGY, 2015, 89 (20) : 10319 - 10332
  • [2] Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys
    Bartlett, EJ
    Amaro-Carambot, E
    Surman, SR
    Newman, JT
    Collins, PL
    Murphy, BR
    Skiadopoulos, MH
    VACCINE, 2005, 23 (38) : 4631 - 4646
  • [3] Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1
    Van Cleve, William
    Amaro-Carambot, Emerito
    Surman, Sonja R.
    Bekisz, Joseph
    Collins, Peter L.
    Zoon, Kathryn C.
    Murphy, Brian R.
    Skiadopoulos, Mario H.
    Bartlett, Emmalene J.
    VIROLOGY, 2006, 352 (01) : 61 - 73
  • [4] The C Proteins of Human Parainfluenza Virus Type 1 (HPIV1) Control the Transcription of a Broad Array of Cellular Genes That Would Otherwise Respond to HPIV1 Infection
    Boonyaratanakornkit, Jim B.
    Bartlett, Emmalene J.
    Amaro-Carambot, Emerito
    Collins, Peter L.
    Murphy, Brian R.
    Schmidt, Alexander C.
    JOURNAL OF VIROLOGY, 2009, 83 (04) : 1892 - 1910
  • [5] Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV 1) by reverse genetics generates attenuated and efficacious vaccine candidates
    Bartlett, EJ
    Amaro-Carambot, E
    Surman, SR
    Collins, PL
    Murphy, BR
    Skiadopoulos, MH
    VACCINE, 2006, 24 (14) : 2674 - 2684
  • [6] Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children
    Englund, Janet A.
    Karron, Ruth A.
    Cunningham, Coleen K.
    LaRussa, Philip
    Melvin, Ann
    Yogev, Ram
    Handelsman, Ed
    Siberry, George K.
    Thumar, Bhavanji
    Schappell, Elizabeth
    Bull, Catherine V.
    Chu, Helen Y.
    Schaap-Nutt, Anne
    Buchholz, Ursula
    Collins, Peter L.
    Schmidt, Alexander C.
    VACCINE, 2013, 31 (48) : 5706 - 5712
  • [7] A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants
    Bernstein, David I.
    Falloon, Judith
    Yi, Tingting
    VACCINE, 2011, 29 (40) : 7042 - 7048
  • [8] Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine
    Yang, Chin-Fen
    Wang, C. Kathy
    Malkin, Elissa
    Schickli, Jeanne H.
    Shambaugh, Cindy
    Zuo, Fengrong
    Galinski, Mark S.
    Dubovsky, Filip
    Tang, Roderick S.
    VACCINE, 2013, 31 (26) : 2822 - 2827